NAMS250516P17500
- 2.20
- 0.000.00%
NewAmsterdam Pharma Newsroom
Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
NewAmsterdam Pharma Company (NAMS) Receives a Buy From TD Cowen
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $42
NewAmsterdam Pharma Price Target Maintained With a $42.00/Share by Needham
NewAmsterdam Pharma Co Analyst Ratings
William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
William Blair Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
NewAmsterdam Pharma Company (NAMS) Gets a Buy From Piper Sandler
Guggenheim Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $41
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Organogenesis Holdings (ORGO)
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Cuts Target Price to $38
NewAmsterdam Pharma Is Maintained at Sector Outperform by Scotiabank
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $52
NewAmsterdam Pharma Analyst Ratings
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Cuts Target Price to $42
William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating